Q1 2020 Earnings Call
Ladies and gentlemen, today's conference is scheduled to begin shortly please continue to standby. Thank you for your patience.
Operator: Ladies and gentlemen, today's conference is scheduled to begin shortly. Please continue to stand by. Thank you for your patience.
Operator: Thank you. BF-WATCH TV 2021 Ladies and gentlemen, thank you for standing by and welcome to the Adaptimmune Q1 2020 Earnings Conference Call. At this time, all participants' lines are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star zero. I would now like to hand the conference over to your speaker today, Ms. Juli Miller. Thank you. Please go ahead, ma'am.
[music].
At this time, all participants' lines are in listen only mode.
After the speakers presentation, there will be a question and answer session to ask a question. During this session you will need a press star one on your telephone.
Juli P. Miller: Good morning, and welcome to Adapt Immune's conference call to discuss our first quarter 2020 financial results. We issued a press release earlier this morning, and I would ask you to please review the full text of our forward-looking statements there. We anticipate making projections during this call, and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC. Adrian Rawcliffe, our CEO, is with me for the prepared portion of this call, and other members of our management team will be available for Q&A. With that, I'll turn the call over to Adrian Rawcliffe.
Please be advised that today's conference is being recorded.
If you require any further assistance please press star zero.
I'd now like to hand, the conference over to your speaker today, that's truly Miller. Thank you. Please go ahead Mike.
Good morning, and welcome to adapt Immunes conference call to discuss our first quarter 2020 financial result.
We issued a press release earlier this morning, and I would ask you to please review the full text of our forward looking statements. There, we anticipate making projections during this call and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the FCC.
Adrian Rawcliffe, our CEO is with me for the prepared portion of this call and other members of our management team will be available for QNX with that I'll turn the call over to Adrian Rawcliffe Act.
Adrian G. Rawcliffe: Thank you, Juli, and thank you, everyone, for joining me. Before I get started, I'd like to officially welcome Gavin Wood to his first AdaptiMeans earnings call. Gavin joined us as Chief Financial Officer in early April. Looking back at the first quarter, the year began strongly.
Thank you Julie and thank you everyone for joining us.
Before I get started I'd like to officially welcome got they work to his first I mean starting school.
Having joined US This chief financial Officer in early April.
Looking back at school. So you have began strongly for us.
Adrian G. Rawcliffe: In January, we announced responses in four new tumors. These are early responses, but they are a validation of our Spear T-Cell platform for people with cancer. We are funded into the second half of 2021, having added close to $140 million to the balance sheet for our deal with Astellas and the public offering in January.
In January we announced responses in cool new tumor indications.
These are early responses, but they are a validation about spear T cell platform for people with council.
We have funded into the second half the 2021, how about having added close to 140 million to the balance sheet bought deal with a stimulus and the public offering in January.
The January clinical data announcement was followed by increases in screening during the first quarter of course fall off clinical trials before the inevitable slowdown associated with cobot Dante.
Adrian G. Rawcliffe: The January clinical data announcement was followed by increases in screening during the first quarter across all our clinical trials before the inevitable slowdown associated with COVID-19. The impact of COVID-19 is still evolving, including its impact on our R&D programs, and the full extent is likely to vary across sites. As a company, we've implemented new ways of working together to reduce the risk of disease. We want to ensure the safety of our colleagues who are working on-site, manufacturing SPIR T-cells for patients enrolled in our clinical trials, all conducting time-critical research activities. I want to thank all our employees, both those who have been working from home and those who have been working in our facilities, to make sure that we can hit the ground running as the situation improves.
The impact it's got to be 19, still evolving including its impact on our R&D programs and the full extent is likely to bury across sites.
As a company we've implemented new ways of working together to reduce the risk of disease spread we want to ensure the safety of our colleagues. So working on site manufacturing spear T cells for patients enrolled in our clinical trials for conducting time critical research activities.
I want to thank all our employees, but those would be working from home and those would be working in our facilities to make sure that we can hit the ground running as the situation improves.
Manufacturing about spear T cells has continued without facilities operating at close to full capacity throughout March.
Adrian G. Rawcliffe: Manufacturing of our spare T-cells has continued, with our facilities operating at close to full capacity throughout March. We are still manufacturing cells for patients in April and May, albeit at a reduced level. And we're optimistic that patients screened and patients for whom we've manufactured cells during the pandemic will be able to participate in our trials as clinical sites resume non-COVID-19-related care. Although many scientific and medical meetings have been delayed or switched to virtual formats, we will continue to communicate our data at these meetings. In a press release issued on April 29th, we laid out expectations for when you would see updates between now and August at ASGCT, ASCO, and the International Liver Congress. Earlier this week, we presented data from our allogeneic program at ASGCT.
We are still manufacturing for patients in April of might well be it's just a reduced level and we're optimistic that patients screened and patients for whom we manufacture itself. During the pandemic, we'll be able to participate in off trials. That's clinical sites. Because you don't have you been 19 relate to cat.
Well, they many scientific and medical meetings have been delayed will switch the book to pullback, we will continue to communicate our data at these meetings.
In a press release issued on April 29, we laid out its expectations. When you would see upside between now and August I guess GCT.
Scott on the international liver Congress.
Earlier this week, we presented data from a allogeneic program, but I guess GCT.
Adrian G. Rawcliffe: We've made great strides in the engineering required to make T-cells from stem cells, including the location and timing of edits to get our T cell receptor into progenitor cells for the generation of T cell banks. We have also been able to produce functional engineered T-cells from stem cells that can kill cancer targets in vitro as effectively as engineered control cells from our autologous product.
We've made great strides in the engineering required to make T cells from stem cells, including the location and timing of edits to get out T cell receptor into progenitor cells for the generation of T cell bikes.
We are also being able to reduce functional engineered T cells from stem cells that can kill cancer targets in Detroit as effectively as engineered control cells from autologous products.
Adrian G. Rawcliffe: These are significant steps in progressing our allogeneic platform towards the clinic. At ASCO, Dr. David Hong of MD Anderson Cancer Center will give an oral presentation with data from the Phase 1 trial for ADPA2M4, our first generation of SPIRT cells targeting MAJ-A4. This presentation will provide a full summary of the trial, including more mature data from patients with synovial sarcoma, as well as data from a broad range of other indications. The acceptance of this abstract as an oral presentation by ASCO is validation of the strength of our ADPA 2M4 program. The full ASCO content will be available online the morning of May 29th, and we will issue a press release with a clinical update that same day. The full ASCO content will also be available in a virtual ASCO booth throughout the day of the 29th Q&A.
These are significant steps and progressing a allogeneic platform towards the clinic.
Hi, Tesco Dr., David homes, MD Anderson cancer Center will give an oral presentation with data from the phase one trial ATP I too am for a first generation spear T cells targeting Vijay full.
This presentation will provide summary of the trial, including more mature data from patients with synovial sarcoma as one of the states. It from a broad range of other indications.
The acceptance of this abstract doesn't oral presentation by SK. His validation of the strengths about 80 P. I too am full program.
The full ASCO content will be available online the morning of my 29, and we will issue a press release, the clinical update that same day.
We will also be available in a book to ASCO two throughout the day of the 29 for Q and I.
We've learnt a lot from the phase 180 pay to import trial.
Adrian G. Rawcliffe: We've learned a lot from the Phase 1 ADPA 2M4 trial. For example, we learned that MAYJ4 is a viable target expressed in a broad range of tumors at levels high enough to garner response. We've learned that the TCR against MAJ-A4 successfully targets MAJ-A4-expressing cancer cells and can result in T-cell trafficking and responses in multiple tumor types. We have used this information to build out our program of assets targeting MAJ-A4.
We've learnt that May J., Paul is a Bible target expressed in a broad range of tumors levels high enough to go into responses.
We've noticed that the TCR against major before successfully talk its major before expressing cancer cells income resulted T cell trafficking I'm responses in multiple Cima talks.
We've used this information to build outs are program of assets toxic Vijay for these include our next generation ATP eight to enforce CB eight cells, which we are testing against a broad range of cancers in us a pulse trial.
Adrian G. Rawcliffe: These include our next generation ADP A2M4 CD8 cells, which we are testing against a broad range of cancers in our SURPASS trial, as well as the radiation sub-study of our Phase 1, and we're on track to present data from both these trials at medical conferences in the second half of 2020. This program also includes a Phase 2 combination trial with ADPA2M4 and a PD-1 inhibitor for patients with head and neck cancer This trial will be called Spearhead 2.
As well as the radiation sub study about phase one trial were on track <unk> dates from both these trials at medical conferences says in the second half of Twentytwenty.
This program also includes the phase two combination trial, we they D. P I too am four and a PD one inhibitor for patients with head and neck cancer. This trial will be called spirit had to all clinical sites will be activated as soon as possible.
Adrian G. Rawcliffe: All clinical sites will be activated as soon as possible. Our Spearhead 1 trial in sarcoma was recently acknowledged by the EMEA's Committee for Orphan Medicinal Products with its adoption of a positive opinion for orphan drug designation for ADPA2M4 for the treatment of soft tissue sarcoma. In Q4 2019, we announced that the FDA had granted Orphan Drug Designation and then RMAP designation to this program. ADPA2 and 4 have clearly demonstrated the potential to offer substantial improvements over the current standard of care for the treatment of advanced soft tissue sarcomas. With these three designations, we believe we're in a strong position to achieve our goal of launching our first product in the U.S. in 2022. Our commercial preparation is ramping up as we add key staff and develop our capabilities towards commercial scale.
A spirit had one trial in Sakakibara was recently acknowledged by the EMEA is committees orphan medicinal products with this adoption of a positive opinion orphan drug designation ATP I too am pool for the treatment of soft tissue sarcoma.
In Q4, 2019, we announced that the S. The I had granted orphan drug designation and then all not designation for this program.
I'd like to him for his clearly demonstrated the potential to offer substantial improvements I have a current standard of care for the treatment of advanced soft tissue sarcoma.
With these three designations we believe we're in a strong position to achieve our goal of launching a first product in the U.S. and 22 inch Jay a commercial preparation is ramping up as we act Keystone and develop our capabilities towards commercial Scott.
Finally, we are progressing 80 P to P program in liver cancer, and we're delighted that Dr. breanna, saying right from the power University clinic in Spain will present data from the third dose cohort at international level Conference in August which was delayed from April.
Adrian G. Rawcliffe: Finally, we are progressing our ADPA2 AFP program in liver cancer, and we're delighted that Dr. Bruno Sangro from the Navarre University Clinic in Spain will present data from the third dose cohort at the International Liver Conference in August, which was delayed from April. We continue to enroll this trial, having progressed to the expansion cohort at doses of up to 10 billion SPIR T cells. As I said earlier, 2020 started strong for us with the validation of our SPIR T cell platform in multiple solid tumors and our most significant deal in the past five years. Now I'll open the call up to questions. Operator?
We continue to enroll this trial, having progressed to the expansion cohort dose is about 10 billion spear T cells.
As I said earlier Twentytwenty started strong for us with the validation of our spear T cell platform in multiple solid tumors and the most significant deal in the past five years now I'll open the call up to questions operator.
As a reminder to ask a question you will need to press star one on your telephone to withdraw your question press the pound key.
Operator: As a reminder, to ask a question, you will need to press star 1 on your telephone. To withdraw your question, press the pound key.
Operator: Please stand by while we compile the Q&A roster. Our first question comes from Marc Frahm with Cowan & Company. Your line is now open.
Standby well, we compile the coupon a roster.
Our first question comes from Mark from with Cowen and Company. Your line is now open.
Yes, thanks for taking my questions.
Marc Alan Frahm: Thanks for taking my questions, and let me just start off by saying you mentioned kind of the counterbalancing, you know, the added interest in the program based on the updates in January, but then, of course, COVID kind of slowed things down. Can you maybe quantify that as to, you know, how much did you see screening increase, you know, maybe in February versus what you'd been seeing in the back half of 2019? And then when we get the update on the press release on the 29th, will that be restricted to May J4, or will we be thinking that that's a broader clinical update of whatever you have across kind of all the programs like you've done some other times?
Just to start off.
Yeah, you much kind of the counterbalancing.
<unk> added interest in the program based on the updates in January.
But then of course your coverage that's one thing sound can you maybe quantify that as to.
How much did you see screening increase you know maybe in February versus what you had been seeing in the back half of 2019, and then when we get the update on the press release on the 29 will that be restricted to me Jay for.
Or do we be thinking that that's a broader clinical update of whatever you have across kind of all the programs like you've done some other times.
Okay. So I'll take the I'll take the second question, but.
Adrian G. Rawcliffe: Okay, so I'll take the second question first, and then I will ask Elliot to comment on the first question and progress on the screening and clinical trials in the first quarter of this year. So in terms of what we will give as a clinical update, I think it's just worth putting the whole thing in context of what's going to be presented at ASCO. David Hong's presentation will be on all of the data we have to date on the patients enrolled in the ADPA2M4 Phase 1 trial.
And then I will Scott Elliott to comment on the.
First question on progress on the.
Screening in the on the clinical trials in the first quarter this year.
So I think the in terms of what we will give us a clinical stage I think it's just we're putting.
The the whole thing in context of what's going to be presented at ASCO Davids homes presentation will be the all the data we have today, John the patients being rolled in the 80 P. Eight to him for a phase one trial.
Adrian G. Rawcliffe: As you correctly stated, this is the first generation of SPIRT cells targeting MAI-J4, and that trial's been ongoing for some time. It's just worth noting that Dr. Hong and the team at MD Anderson have been key partners for us across the range of approaches that we're targeting MAI-J4, including the radiation sub-study, the SURPASS second-generation trial, and you will recall that we had a strategic alliance with MD Anderson as So they are instrumental in treating patients across the range of these studies. The first-generation Phase 1 trial for ADPA2M4 was recruiting across nine different tumor types that expressed MAJ-4, including synovial sarcoma, where we clearly recruited the most patients. Last year, no, actually two years ago, at ESMO 2018, we showed safety from this.
You.
Yes, correct eat steak Vince is they this is the first generation spear T cells toxic Vijay pool, and not Charles Pheno going for some time.
It just worth noting dumped home and the team MD Anderson I'll be a key partners across across the range of approaches that we're targeting Vijay for including the radiation sub study.
The the Pos second generation trial.
You will recall that we had a strategic alliance with MD Anderson as well. So they are they are instrumental in.
Treating patients across across the range of these studies.
The first generation phase one trial, if I'd picture a full was was it was recruiting across nine different tumor types.
Expressing my Jay pool.
Including synovial sarcoma, where we clearly recruited the most patients.
Loss last year I don't got you two years ago as my 20 I'd.
We show safety from this you might remember the first two dose cohorts with full of ovarian patients six ovarian patients I've said hundred million on 3 billion sells it may 29 team. We showed some initial responses in a few sarcoma patients and we showed signs of anti tumor activity and other tumor types.
Adrian G. Rawcliffe: You might remember the first two dose cohorts were full of ovarian patients. Six ovarian patients dosed 100 million and 3 billion cells. In May 2019, we showed some initial responses in a few sarcoma patients, and we showed signs of anti-tumor activity in other tumor types. We updated ESMO and CETOS last year on the sarcoma patients, and roughly half of those patients were responding over that time course. Durability, at that point, was relatively immature.
We updated at ESMO and see toss last year on the sarcoma patients and roughly half of those patients.
Responding over that time course, jure ability at that point was relatively immature.
Adrian G. Rawcliffe: The data cutoff for CTOS was 23rd of October, and we basically used that data cutoff to submit the ASCO abstract, and then subsequently, we announced that we had seen a response in a head and neck patient alongside other responses in our other trials, including those targeting MAGE A4, the radiation sub-study, and the surpassed study, which is the second generation. We have continued to recruit patients through Q4 and into Q1 2020. Overall, we have dosed 38 patients, including six ovarian patients in the first two dose escalation cohorts, followed by 16 synovial sarcoma patients and 16 non-sarcoma patients. Those non-sarcoma patients are split over a wide range of tumors, including ovarian, head and neck, bladder, and lung, and so it's clear that there will be relatively small ends in each tumor type.
The data cuts off the seats AOS was EUR 20, <unk> Teva and we basically use dot data costs all to submit the at ASCO abstract and then subsequently we announced that we had seen their response in I had a net patient alongside other responses in I'd rather trial.
Yeah.
Including those targeting my age for the radiation sub study and the past study, which is the second generation study.
We have continued to recruit patients through Q4 and into Q1 2020.
Overall, we have Doug <unk> 38 to patients and mostly.
Six ovarian patients in the first do dose escalation cohorts, followed by 16, synovial sarcoma patients and 60 known sarcoma patients those non sarcoma patients austerlitz over a wide range of tumors.
Including very head and neck blogs or not.
So you can be it's clear that there will be relatively small ends and each tumor type.
Adrian G. Rawcliffe: Dr. Hong's presentation basically will provide a full update on both the sarcoma patients, including durability of those responses, and also what we've seen outside of sarcoma, and we're quite excited for that presentation, following on from that presentation. We will give an update on the various, So, just to confirm, this includes... An update on progress on Spearhead 1, which is the Phase 2 trial targeting synovial sar An update, i.e.
Jumped homes presentation, basically will provide a full update on both sarcoma patients, including junior ability of close responses.
And also what we've seen outside of soccer and we're quite excited about presentation.
Following on from that presentation.
Which we will give an update on the various trials targeting major rightful.
So just to confirm this includes an update on progress on spearhead one which is the phase two trial targeting with inside I guess I'll cover makes a lot around some lifecycle.
An update.
He more details on the design of the spirit had two trial.
Adrian G. Rawcliffe: more details on the design of the Spearhead 2 trial. This is our Phase 2 trial in head and neck cancer in combination with pembrolism. As I mentioned above, we have seen a response in head and neck cancer in the first generation program as monotherapy. So we know that the SPARE T cell is active in this setting, and we're excited to initiate this trial this year. An update also will be provided on SURPASS, our second generation ADPA2 M4 CD8, where we announced in January that the very first patient of this trial at the lowest dose cohort had responded. Now I want to say, remind everyone that we do plan not to stick to our practice of supplying data at updates at major medical and scientific events.
This is all phase two trial in head and neck cancer in combination with Pembrolizumab.
As I've mentioned above we have seen a response in head and neck cancer.
In the first generation program as a monotherapy so he knows that the space T cells active in this setting a we're excited to initiate this trial this year.
An update also will be provided on supports our second generation ATP eight to ample we'll see the age where we announced in January that the very first patient that this trial at the lowest dose cohorts with responded.
Now I won't say I'd remind everyone that we do plan not to stick to our practice of supplying data.
Updates at major medical and scientific meetings.
Oh, I'm, sorry, but I think will give an overview.
Adrian G. Rawcliffe: But I think we'll give an overview of progress on our entire MAJOR IV targeting program on the 21st. And just to point out, we have previously said that the AFP program will be updated at the International Liver Conference, which has moved from April to August, and Dr. Sangro will give that update on the third dose cohort. So with that, I'll just ask Elliot to comment on the screening, the increase that we saw in the early part of this year. Obviously, we're not going to give specific details on how many patients, etc., but generally speaking, across our trials, Elliot, what color could you add there?
Oh progress on our entire May Jay for we're targeting program on the 29.
And just to point out we have previously said that the I.P. program will be updated at the international never conference in now which is moving from April to walk us doesn't Dod don't decide where we'll get thought updates on the ice cold so with that I'll.
Just ask Elliott to comment on the screening the increase that we saw in in the early parts of this year, obviously I don't want to we don't get to give specific details on how many patients et cetera, but generally speaking across all trials that it well what color can you at that.
Hi, Good morning. Thank you add I would just say that there was a very helpful Bowl increase in interest in our studies from our investigators any conversations.
Elliot Norry: Good morning. Thank you, Ad. I would just say that there was a very palpable increase in interest in our studies from our investigators in the conversations that we had with them, and that really translated into an increase in the actual number of screening patients. As Adrian said, I'm not prepared to, or don't think we should provide specific screening numbers as it relates to individual trials.
That we had with them and that really translated into an increase in the actual number of screen patients as Adrian said.
I'm not.
Prepared to or don't think we should provide specific screening numbers as it relates to individual trials, but I don't think it's surprising that following the announcement of the of the responses that we had seen.
Elliot Norry: But I don't think it's surprising that following the announcement of the responses that we have seen across tumor types and across our platforms, there was an increase in interest. Very great, thank you. Thank you. Our next question comes from Tony Butler with Ross Capital. Your line is now open.
Across tumor types and across our platforms that that there was an increase in interest.
Okay, great. Thank you.
Thank you. Our next question comes from Tony Butler with Roth Capital. Your line is now open.
Yes, good morning.
Tony Butler: Adrian, I just wanted to ask specifically about Spearhead 1 and enrollment in Spearhead One. So there's really two parts to the question. One is, has enrollment continued at a pace that... Let's say it doesn't necessarily protract the outcome of the finality of the trial appreciably. And then, number two. With respect to your comments, Elliot, back in January as it relates to an increased interest in clinical trials
It really just one of them typically about spearhead one.
And enrollment in spear have one so there's really two parts to the question one is has enrollment.
Okay.
What they are doesn't necessarily per truck the outcome of the seasonality of the trial appreciably with today and then number two.
With respect to your comments.
Back in January as it relates to an increased interest in clinical sites and investigators was that you poor snowfall for comment just given the fact that you're.
Adrian G. Rawcliffe: and Investigators, Was that skewed towards synovial sarcoma, just given the fact that you were...
Enrolling a substantial number of patients within that particular disease setting as it relates to spearhead one thing.
Adrian G. Rawcliffe: enrolling a substantial number of patients within that particular disease setting as it relates to spearheading one thing. Thanks, Tony.
Thanks, Thanks, Tony but.
So in regards to.
Adrian G. Rawcliffe: Yeah.
Adrian G. Rawcliffe: Regarding the pace of recruitment for SpareHead1, I would not dispute your statement that what we're seeing continues to give us confidence that we'll be in a position to meet our objective of launching ADPA2 and 4 for patients with sarcoma in 2022. There obviously has been some impact in the sort of mid-March onwards as relates to screening for the SpareHead1 trial, but it is encouraging that we continue to screen patients and manufacture equipment for patients, and we will give an update on that in the May 29th clinical update. With regard to the balance of screening and interest, I would just say this. I think it's worth it, yes, a lot of the patients that we have seen this year are for the Spearhead1 trial. Not surprising.
The.
Pace of recruitment and spare had won.
I I would not disputes your statements that are what we're seeing.
Continues to give us confidence that will be in a position to meet our objective of launching ATP I too am pool for patients with sarcoma in 2022 or that obviously has been some impact in they sort of mid March on woods.
As it relates to screening.
For the spearhead one trial, but it is encouraging that we continued to screen a perrys manufacture for patients and and we will give an update on month.
In the April in the May 29 or clinical update.
With regards to the balance of screening and interest I would just I'd just say this I think it's worth yes, the and lots of the patients that we have seen this year all for the spearhead one trial not surprising that is like 60 patient trial.
Adrian G. Rawcliffe: This is a 60-patient trial. It's much larger than our other trials. It's open in close to 20 centers at this point in time, across Europe and North America, and it's on the back of compelling data, I believe, regarding the efficacy of ADPA2M4 in synovial sarcoma. However, I think I'll just flip to Elliot to confirm that, on the back of the efficacy data, the response data that we put out in January, we also saw an upt Elliot, anything to add to that?
It's much larger than our other trials its opening or close to 20 centers at this point in time across Europe, and North America, and its and it's.
On the back called a compelling data I believe regarding the.
Efficacy of ATP I too am for in synovial sarcoma. However.
I think Oh, just let the Elliott to come from that the we also saw on the back of the efficacy data. The response data that we put out in January we also saw an uptick across other trials and indications as well elliot's anything to add to Bob.
Elliot Norry: Yeah, I would just confirm that Adrian, that we saw robust interest in enrollment across the programs in the early part of the year. And as you said, I think that the interest in synovial sarcoma really mostly came from the data that was presented at Esmone-CITAS last year and just the general knowledge in the sarcoma community about the promise of this therapy. And we expected to have robust enrollment in that study at the beginning of the year as the centers were really opening. Where we really saw a change was in the other studies where it was on the back of the data we presented in January across other tumor types that generated sort of a different type of interest in those programs. So, in summary, the answer to the question is that it really was not restricted to synovial sarcoma but seen across the program.
Yeah, I would just confirmed that adrian that that that.
We saw robust interest in enrollment really across the programs in the early part of the year and as you said I think that that the and the interest in synovial sarcoma really mostly came from.
The data that was presented at ESMO and see taught us last year and just the general knowledge and the sarcoma community.
About the promise of this therapy the.
And we expected to have robust enrollment in that study.
At the beginning of the year as the centers were really opening.
Where we really saw a change.
Was in the other studies, where it was on the back of the data we presented in January.
Across other tumor types that that the generated sort of it a different type of interest in those programs.
So I really in summary, the answer to the question is that it really was not restricted to synovial sarcoma, but that's seen across the programs.
Thank you Elliot Adrian.
Elliot Norry: Thank you, Elliot, and Adrian.
Mohit Bansal: [inaudible] Thank you. Our next question comes from Mohit Bansal with Citigroup. Your line is now open.
Thank you.
Our next question comes from.
Well that Boncel with Citigroup Your line is no [noise].
Adrian G. Rawcliffe: Thanks for taking my question and, very good morning. Hope everyone is staying safe at Team Adaptive Immune.
Great. Thanks for taking my question, then very good money hope everybody stay safe it team Adaptimmune.
Right.
So a big so just wanted to understand and so thanks for providing all the color on the ASCO data you sit possible to put.
Adrian G. Rawcliffe: So, great, so just wanted to understand, and so thanks for providing all the colors on the ASCO data. Is it possible to put the ILC data, the liver meeting data, as well, in context and set expectations there? What should we expect? How many patients are there already? Anything you could provide to help us understand how to feed those data.
The the iOS cdeight that the liver meeting data as Ellen context, and set expectations. There what should we expect how many patients I did already or anything you could provide to help us understand how do how to feed those data.
Elliott.
Elliot Norry: Elliot, would you like to comment on what will be presented at ILC?
Would you like to comment on what will be presented at file C.
So at a at the international live or Congress, we will present the data for a cohort three.
Elliot Norry: So at the International Liver Congress, we will present the data for cohort three. But we're really not.
We're really not.
Elliot Norry: I'm going to announce any of that data in advance of that beyond what has already been communicated, which is the 100% reduction in target lesions seen in the first patient treated in cohort 3 with the approximately 5 billion cell dose. We also do have a poster presentation at the International Liver Congress. Discussing Cohorts 1 and 2 in summary, which we did, they hadn't been updated in total.
Going to announce any of that data in advance of that and beyond what has already been communicated which is on the 100% reduction in target lesion scene.
In and the first patient treated at the end cohort three with the approximately 5 billion.
Cell dose and we also do have a poster presentation at at the international liver Congress.
Discussing cohorts, one and two in summary, which we had.
It they hadnt been updated in total so they're really two presentations one on cohort one and two and then.
Elliot Norry: So there are really two presentations, one on Cohort 1 and 2, and then the presentation by Dr. Sangro on Cohort 3. Okay. Really helpful. Thank you. Thanks, Marc. Thank you. And our next question comes from Jim Bertina with Wells Fargo. Your line is now open. Good morning, it's Nick on for Jim this morning. I have a couple of questions that I wanted to add. The first one is, you know, I know that you're going to be reviewing the design. But is there a reason that people...
The presentation by Dr., saying grow on on cohort three.
Got it really has so thank you.
Thanks, Mike.
Thank you.
Our next question comes from Jim Birchenough with Wells Fargo. Your line is now.
Good morning.
On a Jim this morning couple of questions.
Well yeah. The first one is no I know that you're going to be reviewing.
Said too.
Alaska.
Is there a reason the PD one dosing would just so all the other night, it's legal head and neck cancer.
Is there I mean, I guess I'm trying to get it.
Some way you think you can.
Jim Bertina: Perhaps a different dosing paradigm or a modified dosing paradigm.
Optimized function.
T cells we.
Perhaps different dosing.
Yes.
Ah.
So I think I think I'd, just say well not that we.
Adrian G. Rawcliffe: So I think I'd just say on that we would have given more details on the design of that now. We're going to give more details on the design of that on the 29th, and I'll defer that question until then, if that's okay. Anything else I can help you with?
We if we if we were going to give more details on the design of that now we would have given more details on the design of but now we've got to give more details on the design about on the $20 that I'll defer that question until that about that guy.
Anything else I couldn't help.
Jim Bertina: How did I get to ask it again?
I get to ask it again [laughter] you absolutely well, yes, [laughter] and then I noticed that you have I'm going to solicit decided actually and the target.
Adrian G. Rawcliffe: You absolutely will. Yeah.
Jim Bertina: And then I noticed that you were going to tell us about the first HLA-independent target. Can you give us an example of what an HLA-independent target is, and are these too small to be targeted by a car? How do you decide on a car versus your..., you know, HLN independent TCR?
Can you give us an example of well today July dependent target is and these two small to be targeted.
Oh.
How do you decide on the call.
And.
Strategy.
That but.
Helen Katrina Tayton: That's about it. That's a very good question. I will ask Helen Tayton-Martin to answer that from our side.
That's a very good question I will hand, I would ask Helen type involved into onto a lot.
<unk>.
Yes, I think 10 times, Jim simply questions. So.
Helen Katrina Tayton: Yeah, thanks, and thanks, Jim, for the questions. So I think the simplest way to answer that is the HLA-independent targets that we, the TCR targets that we've been focused on, are effectively CAR targets. So these are self-service proteins. We've obviously looked at the candidates that are well-validated as well as others that are less well-validated but emerging.
I think the simplest way to want to that is the h. lay independent targets that we think T. I talk I said, we've been focused on effectively called targets. So these are sell stuff its pricing.
Well the heat up because they see the candidate for the wealth I would say 'cause it as well is like I said that well validated that.
Helen Katrina Tayton: And I think, really, an HLA-independent TCR is a TCR that can recognize, specifically, a cell surface protein and really then signals through the TCR. It behaves like a TCR on a T cell. But what we've been able to do is find these very, very rare TCRs and then put them through our internal proprietary processes for specificity testing, potency, and efficacy. And that's really the basis of the targets that we're going after in that platform. So it's very exciting. It leverages all of the TCR capability and functional behavior, but it is obviously not HLA-restricted. So we haven't disclosed the first target, but we've agreed with Astellas that, obviously, it will be a hit. I hope that answers the question.
But emerging I think really nicely in between that TCR is a TCR got can recognize specifically I felt that its pricing I agree it's been signals treated CCR pace I can see yeah.
On a T cell, but what we've been able to do is find these very very bad PCR that then put them through our internal proprietary crisis is for specificity testing.
And I can see an efficacy and at that that that's really the basis of the targets that were getting off there in that platform. So it's very exciting it leverages all at the TCR capability and functional.
Hey, good but it is obvious you know I hate to lay restricted says well we haven't disclosed to the first targets. We've agreed with Astellas I'm Lucky that we it will be a targets.
Okay. The question.
Jim Bertina: Certainly, partially. So do you, do you, are you selecting something that, um... Do you do a head-to-head with a car, or is this just a way to target HLA-independent proteins without having to..., develop or use car technology? I guess the point is, we always hear that, you know, car T cells can lie in targets with
Certainly partially so do you do you you selecting something that.
You do a head to head with Oh or is this just a way to.
Target actually dependent proteins without having to.
Well use of course.
I guess the point is we feel is here that.
Car T cells combined targets.
No Oh, Hey, Sajan density.
Oh no.
No Yeah, you know mature T on it.
Helen Katrina Tayton: a non-spear, you know, matured TCR, but CAR T is at a position of being more potent, if you like PCR-based therapies.
<unk> and so position to be huge.
You like.
TCR based therapies.
Helen Katrina Tayton: Um... So, actually, I think that, you know... seeing much more surface antigen, but the idea of a finely tuned specific TCR that can see a fragment of that self-service protein is really the design behind a functional TCR that can recognize a self-service protein. Proteins. So we think that there are advantages in our preclinical testing. You wouldn't be surprised to know that we do do head-to-head comparisons, and I think that's what's given us a huge amount of enthusiasm and excitement around this program. So we've been able to generate them, we test them in comparison to published CARs on well-known targets, and we've been able to fine-tune them in terms of their potency and specificity.
So actually I think that you know.
Thank you all these targets normally they play it's easy for you like frequency, so operator levels and that's all having Uh huh.
Citic TCR is it is critical I think you can apply similar sort of dynamics itself that its protein typically medical proteins and a car is it's a is seeing much more surface antigen, but the you know the idea oh they find leaching.
If it specific TCR that can see segment of that felt that this protein is it's really the bit design behind a functional PCR that can recognize the south Africa.
Machines say, we think that there are advantages in a preclinical testing. He would you wouldn't be surprised to know that we do you do head to head comparisons and I think that's what's giving us a huge amount of comparing a fan enthusiasm and excitement around its program. So we've been able to generate them testing capacity published columns on <unk>.
Well named target.
And we've been able to fine tune them intensive potency and specificity.
Jim Bertina: It's very helpful. And just the last one from me on AFP: obviously, you started this program with a healthy degree of trepidation. Now that you're at, you know, very high doses of cells, Is there a concern that there is, you know, enough variability in healthy tissue? Possibly that there are rare events that are safety events that you're not really going to be able to discount until you treat them in tens of hundreds of patients. How confident are you? You know got past this concern about Cellular Health Tissue Toxins.
Right. It's very helpful. Then slawson per meal on T., obviously, you started this program.
Uh Huh healthy to Korea trepidation.
Now that Youre.
Very high doses ourselves.
Are you sort of concern that there is nothing already ability in healthy tissue.
[noise] potentially that Oh, you know rare events.
Not really comes to be able to discount to treat.
Tens or hundreds of patients to how confident are you.
Uh huh.
Cool Pos is concerned about.
Until the deal to she talks.
I lost gallium to.
Elliot Norry: I'll ask Elliot to take a stab at that.
Elliot Norry: Yeah, thanks. Thanks for the question. I mean, I think that I would say that we have increasing confidence with each patient that we treat and see that there's an absence of liver toxicity associated with the TCR. I think your point's well taken. Could there be a rare patient that has a level of expression that's high enough to generate such a response, and will we know that without treating many, many more patients? I think that... In the world of clinical safety, until you've treated that number, it's hard to make assumptions about that. But to date, we haven't seen liver toxicity that would be of that type of concern to us.
Take a stab without.
Yeah. Thanks. Thanks for the question I mean, I think that I would say that that we have increasing confidence with each patient that we treat.
[music].
And see that there's an absence of liver toxicity associated with with.
The TCR and so.
I think your points well taken could there be a rare patient that has a level of expression. That's a that's high enough to to generate such response.
And it will we know that without treating you know many many more patients.
I think that.
In the world of clinical safety and until you've treated that number it's hard to make assumptions about that.
But.
To date, we haven't seen liver toxicity that would be of that type of concern to us. So we're gaining increasing confidence in in in the product and actually just the number of patients that we've treated to date and and seeing safety at the highest cell dose does give us a increase.
Jim Bertina: So we're gaining increasing confidence in the product, and actually, just the number of patients that we've treated to date and seen safety at the highest cell dose does give us increasing confidence. Great. Thanks a lot for answering my questions. I'm trying to picture what your virtual ASCO booth will look like.
In continent.
Great. Thanks.
Actually my question.
On a picture what Youre virtual ask a booth will look like that.
Jim Bertina: Thanks Nick, thank you. As a reminder, ladies and gentlemen, that's the star, then one to ask a question. Our next question comes from Jonathan Chang with SVB Leerink. Your line is now open. Hey guys, this is David Roushon for Jonathan. Thanks for taking our questions and congratulations on the progress. Just to go back to that last question a little bit, you mentioned the AFP program had progressed to the 10 billion cell expansion cohort, and you've talked about the safety profile already, but I was wondering how you think about dose escalation from here, and when do you think we might see updates from these later cohorts?
[laughter] Thanks, Nick.
Thank you as a reminder, ladies and gentlemen that Star then one to ask your question.
Our next question comes from Jonathan Chang with SVB Leerink. Your line is now.
Hey, guys. This is David Rouge on for Jonathan Thanks for taking our questions and congratulations on the progress.
Just to go back to that last question a little bit you mentioned the assay program had progressed to the 10 billion cell expansion cohort and you talked about the safety profile already but was wondering how you think about dose escalation from here.
And when do you think we might see updates from these later cohorts.
<unk>.
So I just.
Wei Ji Chang: So I'll just... give you an idea of the timing for data updates and then I'll ask Elliot to comment on the dose ranging that we're seeing and what our thoughts are about that. So... We previously indicated that we would provide an update on cohorts on the dose escalation at the International Liver Conference. That was subsequently moved from April to August, and as Elliot talked about earlier, that will be the case. We also, at the same time that we provided that guidance, provided guidance that we would update on the expansion cohort patients that we recruited in the second half of 2020, and we think that remains a reasonable goal for us at this point in time. And so that's when you should anticipate. I will point out, I just want to, in an abundance of caution.
Put out on that in terms of the timing for dates are updike's that all scalia to comment on a the dose ranging that we're seeing and what we what our thoughts are about that so.
We previously guided.
That we would provide a updates on cohorts on the dose escalation.
The international liver come from slot that was subsequently mood from April to August and as Elliot talked about earlier that will be that will be the case. We also at the same time that we provided that guidance. We provided guidance that we would update or on the expansion cohorts patients that we recruit.
In the second half Twentytwenty, and we think that remains a reasonable goal for us at this point in time, I'm, sorry, Dot Dot Dot dot is when you should anticipate I will point out yeah, I just want to I just want to.
In the abundance of caution.
Adrian G. Rawcliffe: We, small numbers of patients are very meaningful for us. This trial is now recruiting at the expansion level. The advantage of that is a lack of stagger between patients. However, this is still an early phase one trial, and we're still evaluating safety at this level, et cetera. And so I would not anticipate hundreds of patients in the update in the second half of this year, but I think we hope to give a meaningful update on patients enrolled in the expansion cohort. Elliot, thoughts on dose escalation.
We small numbers of patients are very meaningful for us. This trial is now recruiting at the expansion.
The expansion level the advantage of that is a lack of styka between patients. However, this is still the early phase one trial and we're still evaluating safety at this level et cetera.
So we I wouldn't anticipate hundreds of patients and the updates in the in the second half of this year.
I think we have you been meeting for an update on the phone patients enrolled into the expansion cohort that.
[noise] Elliott thoughts on dose escalation.
I would just say that you know this study is designed and at this point too as Adrian mentioned to treat patients with that doses up to 10 billion cells in the expansion phase with how to stagger.
Elliot Norry: I would just say that, you know, the study is designed at this point to treat patients with doses up to 10 billion cells in the expansion phase without a stagger, and we don't, there's no plan to escalate the dose beyond that. We're really looking to accumulate a number of patients' experience with that cell dose and make further decisions from there. Got it, thank you, that's helpful. And you mentioned the durability data from the sarcoma patients from the ADP. The A2M4 study will be presented at ASCO. How are you thinking about competitive benchmarks in the sarcoma space? And could you help that expectation?
And Ah, we don't there's no plan to dose escalate beyond that.
We're really looking to accumulate a number of patients experience.
With that cell dose.
And and to make further decisions from there.
[laughter].
Got it. Thank you that's helpful and you mentioned the durability data.
On the sarcoma patients from the ATP.
I hate to enforce that he would be presented at ASCO. How are you thinking about competitive benchmarks in the sarcoma space and could you help set expectations here.
<unk>.
Elliot Norry: Elliot, would you like to talk to them?
Elliott would you like to talk to them.
I'm sure so from the standpoint of competitive benchmarks eye in the second line setting after a systemic chemotherapy for the treatment of sarcoma was.
Elliot Norry: Sure. So, from the standpoint of competitive benchmarks, in the second-line setting after systemic chemotherapy for the treatment of sarcomas, the second-line therapies that are currently approved and or used regularly are typically associated with response rates in the 5% to 15% range and are associated with a degree of toxicity depending on the treatment. And the treatments are generally ongoing treatments where patients have to return time after time for therapy. When, When we're seeing 50% response rates, and the durability will be discussed, and as of CTOS, we're seeing durability out to nine months. You know, that represents, we believe, an advantage to those patients as compared to what's currently available. And, um, and, uh, The Advantage of a Single Therapy that allows patients to, you know, go through a treatment with... that does have a degree of toxicity but wants Resolved can enjoy a period of time without further ongoing week-to-week or month-to-month treatments is also part of the advantage to the patient. So I'll leave it at that. But I think that's really how we see it.
The the second line therapies that are currently approved and or use regularly are typically associated with a response rates in a 5% to 15% range and are associated with.
A degree of toxicity, depending on the treatment and.
And.
The treatments are generally ongoing treatments, where patients have to return a time after time for therapy. So.
When.
When we're seeing 50% response rates and you know the durability will be discussed and as of as a C cost we were seeing a durability out to nine months.
You know that represents.
We believe in advantage to those patients as compared to what's currently available.
And.
And.
The advantage of a single therapy, a that allows patients to go through a treatment with.
That does have a degree of toxicity, but once.
Resolved can enjoy a period of time without further ongoing you know week to week or month to month treatments and also as part of the part of that advantage to the patients.
So I'll leave it at that but I think that that's really how we see it.
Got it I would just.
Wei Ji Chang: Got it. Thank you so much.
Spectrum.
Wei Ji Chang: Thanks.
Okay. Thank you.
Mara Goldstein: Thank you.
Mara Goldstein: Thank you. Our next question comes from Sarah Goldenstein with Mizuho. Your line is now open. Hi, thank you. This is Mara, actually.
Thank you. Our next question comes from Sarah Goldenstein with Mizuho. Your line is no.
Hi, Thank you.
Actually just a question on me the allogeneic that TCR T. programming and can you just outline for us how we should anticipate that that would progress and what are the milestones within that program, we should look for interest.
Mara Goldstein: Just a question on the allogeneic TCRT program. Can you just outline for us how we should anticipate that that would progress, and what are the sort of milestones within that program we should look for? And just in addition to that, you know, on the approach that you're taking, are there ways in which, as you look to, you know, develop therapeutically, you can somehow also increase antigen presentation on HLA? Are there approaches that allow you to do that, and would you consider that?
Addition to which you know any approaching you're taking or are there ways in which as you look to develop therapeutically that you can somehow also increased antigen presentation on each other approaches that allow you to do that in would you consider that.
So thanks, Thanks Mara.
Helen Katrina Tayton: So, thanks Mara. I will ask Helen to talk about the allogeneic piece.
Oh Catalan to talk to the Allergan I base.
And I think that's the question so.
Helen Katrina Tayton: Thanks for the question. So, as you will have seen, our approach is focused on developing T cells from iPSC stem cells, and that's been a focus of ours for some time, and that's where we've made the most progress with the recent presentation this week at ASGCT, where we actually were able to determine the right location to put in a TCR into those edited, then differentiated stem cells into T cells. So there's a lot of research that's been performed to sort of get to that stage, and it's important to generate a cell where we are basically removing class one and the endogenous TCR and putting in a suicide gene that enables those cells to be stopped if we need to. So the last step for us was actually getting a TCR into a functional location by editing and differentiating it into a functional cell. So that's a huge step forward to produce a T cell in that setting.
As you will sustain our purchase is focused on developing T cells from I guess he stem cells that that's.
Then a FX Oh I've asked if something for some time at that squarely at night.
The most progress a with recent presentation. This week at ASCII team.
Well, we actually were able to determine the right location to put in a TCR into those edited then differentiated stem cells to T cells. So there's a lot of research that's going to sort of and been performed to sort of get to that stage and it's important to generate so wherever we are they.
Lastly, I really think close one and the endogenous TCR and putting in a suicide team that enable say cells to be and started if we need to say the lost that for us was actually getting a TCR into a functional location from editing and differentiating into a functional Sal.
It's a huge that that's a huge that pool. It typically is a a T cell enough setting.
You know, what that's where the the next step so really around confirming any and you have that final at its we may need to and then beginning the process development work into a ticket so banks. It can go into the clinic.
Helen Katrina Tayton: Then the next steps are really around confirming any other final edits we may need to do and then beginning the process development work to get cell banks that can go into the clinic. We have started all of those processes. And so to answer the question in terms of milestones, that will be obviously IND filing and heading to the clinic. And we haven't, there are a number of moving steps on that which we haven't bottomed out yet. So we're not talking about specifics of the timelines, but that is on our horizon. And obviously, we have our own programs which leverage that for our MAJ-4, and then we have new programs through the Acellus collaboration which will be coming along behind. And the second question, sorry, if that's repeated, I'm not sure whether you want me to answer that or whether that's another member of the team.
And we know we started with they they've persisted and say you know why the next into on the question in terms of milestones.
That will be we see R&D filing and heading into the clinic and we haven't that there are number new baby steps on that which we havent bottomed out yet so when we're not talking about specifics the timelines, but that is on our horizon.
And obviously, we have already programs, which I left except for a major before that we have new programs Streeteasy Bacillus cooperation that will be coming along behind.
The second question out I am sorry, perhaps or if that's true repeated I'm not sure. What do you want me to one stop or whether that's a another member at the team yeah.
Mara Goldstein: Mara, could you clarify your second question about driving HLA currently?
All right could you clarify your your second question about driving a July presentation.
Mara Goldstein: Yeah, so I'm just wondering, within the context of the discussion around CAR versus TCR, about sort of approaches where you could increase the amount of expression or neoantigen expression on cells so that you could use that in combination with the existing TCR-T program, that's all.
So I'm just wondering but within the context of you know the discussion around car versus TCR I'm, just wondering around sort of approaches where you can increase the amount of expression or neoantigen, especially on cell. So that you could you got in combination with existing within existing TCR T program.
That's all.
Yeah.
Adrian G. Rawcliffe: Yeah.
So so <unk> what I'd say is we have we have looked at approaches whereby you might increase presentation Oh by July it onto journal on cells.
Adrian G. Rawcliffe: So all I'd say is we have, we have looked at approaches whereby you might increase presentation of HLA and antigen on cells. However, that's not the current preferred approach to driving for increased efficacy.
That's not the tolerant preferred approach to driving for increased efficacy, we referred on to a number of other approaches was sort of next generation approaches.
Adrian G. Rawcliffe: We've referred to a number of other approaches as sort of next generation approaches, including the approach that we're currently in the clinic with CD8 in terms of converting our T-cells. A well-designed T cell receptor should, and it should, in its normal state with the right affinity be able to track down cells with very low expression. As Helen referred to earlier, I think it's a bit of a myth that TCRs are less potent than CAR-T driven cells. I think the antigen presentation of a typical surface antigen on a cell, particularly in the context of something that's floating around in the bloodstream and therefore immediately available for a CAR-T in the hematological setting, is orders of magnitude higher than is typically seen by HLA presentation.
Including the approach that were currently in the clinic with CDIY.
In terms of converting all T cells.
The overall rationale for Bob I, just want to be clear its a.
Yeah, well designed T cell receptor.
Sure.
And it's normal site would refer that to be able to track down.
So with very low expression as Helen referred to earlier I think it so it it's a bit of amid the T. C of O less potent bond car T. Three themselves I think I think the antigen presentation of us a typical surface antigen on the so particularly in the context so.
Something that's floating around in the bloodstream example, immediately available for coffee in the Haematological setting is he's orders of magnitude higher than they typically seen by July presentation, and yet in the natural system I did T cell receptor is naturally able to find a normal antigen presentation.
Adrian G. Rawcliffe: And yet, in the natural system, the T cell receptor is naturally able to find normal antigen presentation for viral antigens, etc. And so, indeed, the TCRs we've managed, we believe that they can track down very low, relatively low levels of HLA presentation of cells. And so the question, therefore, for our perspective, is not necessarily how do you drive HLA and antigen presentation.
Viral antigens, etcetera, and so and I Indeed, all TCR as we manage we we believe that they can track down very low relatively low level was Oh I July you presentation I'm all of Upsells and so the question that fourth broad perspective is not necessarily how'd you draw feature like an antigen.
Presentation with the associated risks off the that would come with but Rob how do you improve the functionality of the T cell through a number of on that second generation approaches in order to enable it to either be more potent to traffic to the GE about or to overcome the tumor micro environment.
Adrian G. Rawcliffe: with the associated risks that that would come with.
Adrian G. Rawcliffe: but rather how do you improve the functionality of the T-cell through a number of our next second-generation approaches in order to enable it to either be more potent, to traffic to the tumor, or to overcome the tumor microenvironment?
Okay. Thank you.
Mara Goldstein: Okay, thank you.
Mara Goldstein: Thanks a lot.
Thanks, Bob.
Jim Birchena: Thank you, and our next question is a follow-up from Jim Birchena with Wells Fargo. Your line is now open. Just one more on the iPSC T-cell, and that is, are you just able to make CD8 T-cells at the moment, or are you able to make CD4 T-cells as well, and given what you've done with second-generation A2M4, are you putting CD8 into those?
Thank you and our next question as a follow up from Jim Birchenough.
Fargo. Your line is no.
Hi, just one more on the I.P.S.C.T. cell and that is a you just able to make C. D E. T cells at the moment or are you able to me.
Cdfour T cells as well.
Given what you've done wait a second generation a two way before are you, putting cdfour and Cdeight T cells. Thanks.
Jim Birchena: This is with respect to our allogeneic program.
This is with respect to our allogeneic program.
Jim Birchena: Yes, correct. Yes, Helen...
Yes, correct, Yeah, I had would you like to comment on that.
Helen Katrina Tayton: Yes, Helen. Would you like to comment on that?
So so the answer is yes, we can make CD fools can take a couple for kids and we will say getting to a single positive TD eight so that's all through differentiation of the T cells to stem to T cell.
Helen Katrina Tayton: Sure, so the answer is yes, we can make CD4, CD8, double positive, and we're also getting to single positive CD8 cells. That's all through differentiation of the stem cell into a T cell. So it's not through adding CD8 in that sense, but that's a specific element that we have used in our autologous second-gen program. So in the allo space, we have focused on differentiating the iPSCs to a functional CD4, CD8 positive, and then CD8 T cell. We still have some work to do, but that's basically the phenotype we've been driving for, and that's the functionality we've been starting to show most recently in this week's post. Thank you.
It it's not true.
Adding TD eight and nothing that's a specific I meant that we have used in our autologous second Gen program. So in that in the Allied space. We have focused on a differentiating VIP functional 60, 48, plus 10 minutes Cdeight T.
He said, we have to see what to do but that's basically the phenotype weakened guiding for enough that functionality. We can starting to said in most recently in this week's type stuff.
Adrian G. Rawcliffe: Okay, thank you. Bye-bye. I am not showing any further questions at this time. I would now like to turn the call back over to Adrian Rawcliffe for any closing remarks.
Okay. Thank you.
Thanks.
Thank you.
I'm not showing any further questions at this time, so now like to turn the call back over to Adrian Ross for any closing remarks.
Thank you.
Adrian G. Rawcliffe: We've made real progress in the first part of 2020, pushing forward with our product in sarcoma and generating encouraging responses across a broad range of solid tumors. And I'm looking forward to sharing more data on May the 29th at the beginning of... I'm more confident than ever that the work we do is making and will continue to make a difference for people with cancer. And with that, we'll close the call. Thanks a lot.
We've made real progress in the first part or Twentytwenty pushing forward without product in sarcoma and generating encouraging responses across a broad range of solid trimas and I'm looking forward to sharing more data on may the 29th at the beginning of basket.
More confident than ever the work, we do is making and we'll continue to make a difference for people with cancer and with that will cause the cool. Thanks a lot.
Ladies and gentlemen, this concludes today's conference call. Thank you for participating you may now disconnect.
Operator: Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.
[music].